Glaxosmithkline Biologicals Sa

Sumana Chandramouli

Andrea Carfi

Ethan Settembre

Kate Luisi

Matthew James Bottomley

Enrico Malito

Newton Muchugu Wahome

Marco Biancucci

Kunal Bakshi

Zihao Wang

Marcin Krzysztof Bugno

Matthew Albert Tyson

Mark Jonathan Wilson

Ethan C Settembre

Modified HCMV gB proteins in a non-post-fusogenic conformation, compositions comprising such proteins, and uses thereof.

Modified human cytomegalovirus proteins

Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.

Modified cytomegalovirus proteins and stabilized complexes

The invention generally relates to recombinant human cytomegalovirus (CMV) gB proteins and immunogenic fragments thereof, which do not comprise a transmembrane (TM) domain; and comprise one or more mutations that reduce the aggregation between the monomeric trimers of gB, and/or adhesion of the monomeric trimer of gB to the host cell.

Cytomegalovirus antigens

The present invention is directed to mutant parvovirus VP1 unique region polypeptides, compositions comprising such polypeptides, methods of making such compositions, as well as methods for identifying the likely presence of parvovirus-neutralizing antibodies, and methods for assessing the functional immunogenicity of parvovirus vaccines and measuring a correlate of efficacy to assess a treatment for parvovirus infection.

Parvovirus Vp1 unique region polypeptides and compositions thereof

Growing community of inventors

Cambridge, MA, United States of America

Sumana Chandramouli